Log In
Print
BCIQ
Print
Print this Print this
 

LIPO-202

  Manage Alerts
Collapse Summary General Information
Company Neothetics Inc.
DescriptionSubcutaneous formulation of salmeterol, a long-acting adrenergic receptor beta 2 agonist (LABA)
Molecular Target Adrenergic receptor beta 2 (ADRB2)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationBody Fat
Indication DetailsReduce subcutaneous abdominal fat
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today